Predictive Values of Post-Treatment Adenosine Diphosphate???Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients, The American Journal of Cardiology, vol.104, issue.8, pp.1078-1082, 2009. ,
DOI : 10.1016/j.amjcard.2009.06.007
Ticagrelor versus clopidogrel in patients with acute coronary syndromesN, Engl J Med, vol.36, pp.1045-1057, 2009. ,
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study, European Heart Journal, vol.35, issue.41, pp.3070-3078, 2017. ,
DOI : 10.1093/eurheartj/ehu161
Is There an Ideal Level of Platelet P2Y 12 -Receptor Inhibition in Patients??Undergoing Percutaneous Coronary Intervention?, JACC: Cardiovascular Interventions, vol.8, issue.15, pp.1978-1987, 2015. ,
DOI : 10.1016/j.jcin.2015.08.032
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCIJAMA, pp.1215-1223, 2011. ,
ADAPT-DES InvestigatorsPlatelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyLancet, pp.382-614, 2013. ,
Working Group on On-Treatment Platelet ReactivityConsensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingJ Am Coll Cardiol, pp.62-2261, 2013. ,
Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine, al. Bleeding and stent thrombosis on P2Y12- inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J, pp.854-863, 1999. ,
DOI : 10.1016/j.jcin.2013.04.009
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel, Journal of Thrombosis and Haemostasis, vol.59, issue.10, pp.1999-2005, 2012. ,
DOI : 10.1016/j.jacc.2012.02.026
GRAVITAS InvestigatorsStandard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialJAMAA randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI, Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) studyJ Am Coll Cardiol, pp.1097-1105, 2011. ,
ANTARCTIC investigatorsPlatelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trialLancet, ARCTIC InvestigatorsBedside monitoring to adjust antiplatelet therapy for coronary stentingN Engl J Med, vol.367, pp.2100-2109, 2012. ,
Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)Eur Heart J, pp.37-267, 2016. ,
LEADERS FREE InvestigatorsBiolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-studyEur, Heart J, pp.38-961, 2017. ,
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study, Circulation, vol.121, issue.10, pp.1188-1199, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.919456
Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel, JACC: Cardiovascular Interventions, vol.6, issue.2, pp.158-165, 2013. ,
DOI : 10.1016/j.jcin.2012.09.012
Effectiveness of switching 'hyper responders' from prasugrel to clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyInt CAPITAL InvestigatorsA randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS StudyThromb Haemost, J Cardiol, vol.168, pp.5004-5005, 2013. ,
Long-Term Safety of Drug-Eluting and??Bare-Metal Stents, Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trialThromb Haemost, pp.2496-2507, 2015. ,
DOI : 10.1016/j.jacc.2015.04.017